Podcasts about Pharma

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharma ads, biotech IPOs, $1M longevity programs, oh my!This month's Digital Health Download skews towards biotech, which is having a moment. Tune in to hear Halle and Michael cover the latest headlines.We cover:Why pharma ads are surging and the growing push for restrictions on D2C drug advertisingHims & Hers' $1.15B acquisition of Eucalyptus, its global expansion strategy, and the FDA crackdown on compounded GLP‑1 drugsThe return of biotech IPOs, with Eikon Therapeutics and Generate Biomedicines signaling investor interest in platform‑based drug discoveryVaccine makers scaling back research amid policy uncertainty, declining uptake, and tighter fundingTrumpRx's “most favored nation” drug pricing approach, and what one STAT analysis foundBryan Johnson's $1M per year “Immortals” longevity program—Show notes:Should drug companies be advertising to consumers? (The New York Times) Hims & Hers Enters $1.15 Billion Agreement to Acquire Eucalyptus (PharmExec.com)A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all (STAT)Vaccine Makers Curtail Research and Cut Jobs (The New York Times) TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics (STAT)Bryan Johnson's Immortals: $1M to try longevity regimen (Axios) —"Halle Tecco wanted to see tech used for better medical services and getting people engaged in their own health. Now, she's written a book on how she went about it." - The WSJMassively Better Healthcare is out now!—Rock Health's annual CEO Summit is returning to the New York Stock Exchange on March 27th! Learn more and nominate a CEO to join this invite-only event here. —

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Brigham Buhler is a healthcare entrepreneur, founder and CEO of Ways2Well, and co-founder of ReviveRx Pharmacy. https://ways2well.com EPISODE LINKS https://www.instagram.com/brigham.buhler https://ways2well.com SPONSORS https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Becoming the first drug rep for Cialis 04:47 - The primary care problem in America 07:20 - Why you should self-pay prescription drugs 12:10 - The dirty secret of anti-depressants 16:13 - The prescription drug incentive program 21:27 - 5 insurance companies cover 90% of Americans 23:31 - The Pharmacy Benefit Managers scam 28:48 - Think of health insurance like car insurance 31:27 - The #1 mistake we're making with our health 34:26 - The testosterone myth 38:51 - Why it costs $250M to bring a drug to market 44:32 - Why health insurance keeps you in the dark 45:31 - How we're fixing problems in healthcare 49:58 - How Brigham ended up on JRE 53:17 - Lobbying against peptides with the FDA 01:00:34 - Why "FDA-approved" products aren't always safe 01:06:08 - The "problem" with peptides 01:08:02 - The origin of the opioid crisis 01:11:48 - Pediatrician's vaccine schedules 01:17:55 - Changes in child vaccine requirements 01:21:41 - How fast medical knowledge becomes antiquated 01:25:21 - Why RFK backed down on vaccines 01:29:49 - Importance of flipping the food pyramid 01:33:44 - Combining IGF + GLP-1 drugs 01:36:50 - Jelly Roll's weight transformation 01:44:19 - Small wins = huge progress 01:47:44 - Brigham's efforts in the MAHA movement 01:54:15 - FDA's response to MAHA 02:00:01 - Protecting healthcare from future administrations 02:06:55 - American healthcare vs. other countries 02:08:44 - Food ingredients in US vs. Europe 02:15:15 - New stem cell treatments 02:17:06 - Why stem cells were banned in America 02:22:17 - New Japanese stem cell discovery 02:28:33 - Early anecdotal results from stem cell therapy 02:31:51 - We can create real-life X-Men 02:36:24 - Psychedelics & super soldiers 02:42:26 - The MINDS project (psychedelic problem-solving) Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Banks Bourne, Founder & Chief Executive Officer at Bourne Partners.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Banks, covering:   How making a bet in the right place at the right time sparked an extraordinary journey in pharma investing. The founding of Bourne Partners and a twenty five plus year ride through multiple market cycles. Lessons from hundreds of deals, and why the best investments are often the most complex and hardest won. Why running from ego and listening obsessively to clients is one of the most underrated advantages in private equity. Why private equity has become increasingly commoditised, and why Banks believes momentum is building and sentiment is turning positive heading into 2026. As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners. He and the firm have been party to more than $10 billion of transactions in the pharmaceutical (“pharma”), pharma services, and consumer healthcare sectors. Banks is also the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization, and clinical trials services to patients and partners in more than 100 countries.   For almost 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks' initial investment in King Pharmaceuticals in the late 1990's. This investment introduced Banks to the pharmaceutical world and jump started his interest in the healthcare sector. Since then, he has invested in more than 200 private companies / assets.   While Banks has derived great satisfaction by offering focused advisory services to, and investing in, pharma, healthcare, and consumer-oriented companies that need strategic and operational insights, he is even more gratified knowing that his work has helped companies to improve the health and well-being of patients across the world. Banks is passionate about providing healthcare, and specifically pharmaceuticals, to less fortunate patients, as demonstrated by supporting The Max Foundation, Partners in Health, The Bourne Foundation, The Levine Children's Hospital, and other non-profit organizations. He received a B.A. degree in Business Management (Magna Cum Laude) from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO). Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Meet Kim Jablonski, the former Chief Compliance and Ethics Officer at Bristol Myers Squibb, where she navigated the complex world of pharmaceutical ethics. With nearly her entire career at this global giant, Kim juggled legal challenges, corporate responsibilities, and raising three kids. Join us as she shares her journey, insightful lessons, and why ethical decision-making is more than just a checklist—sometimes, it's a bit of a balancing act! SHOW NOTES 00:44 Career Journey: From Law to Compliance Leadership 04:33 Creating Impact in Compliance and Ethics 07:32 Emphasising Good Decision-Making Practices 13:01 Navigating Challenges in the Biopharma Industry 22:21 Innovations and Cultural Insights in Global Teams Transcript and more GRC content: https://www.riskywomen.org/2026/02/podcast-s9e5-leading-with-integrity-in-pharma-and-at-home-kim-jablonski/

America Out Loud PULSE with Dr. Vaughn & Dr. Tankersley – Of the 25 top industries in the country, recent polls now have PHARMA as 24th and the healthcare industry as 23rd, both barely exceeding the federal government at the bottom of the list. The solution to almost all of these issues is always the same- returning to a foundational trust in the eternal truths...

Prefabrication works differently in highly regulated environments. In this episode of Prefab, Unfiltered, recorded live at Advancing Prefabrication, Todd Weyandt sits down with David O'Connell to explore how prefabrication, modular construction, and industrialized strategies perform inside life sciences, pharmaceutical manufacturing, and cleanroom construction. When time to market can mean tens of millions of dollars per day, construction strategy becomes a business-critical decision. But in regulated environments, every weld, inspection, and document must meet strict compliance standards. This conversation unpacks where prefabrication truly adds value in pharma and semiconductor projects, where full modular building approaches struggle, and why regulatory alignment is often the deciding factor. If you are involved in life sciences construction, cleanroom facilities, modular construction, or industrialized project delivery, this episode delivers a grounded and practical perspective.   You'll Learn Why full building modular often struggles in life sciences construction Where prefabrication works best in pharmaceutical and cleanroom environments How regulatory inspections shape prefab strategy Why partnering with agencies having jurisdiction is critical How time to market drives construction decisions in drug manufacturing The financial impact of schedule acceleration in regulated facilities   Meet Our Guest David O'Connell brings decades of experience across semiconductor, life sciences, and pharmaceutical construction. With a background shaped by multiple generations in construction and deep experience delivering highly technical facilities, he has worked at the intersection of prefabrication, regulatory compliance, and time-critical project delivery. His perspective bridges traditional construction methods and modern industrialized strategies, particularly in cleanroom environments and drug manufacturing facilities where documentation, inspection, and compliance are paramount.   Todd Takes Prefabrication Has to Respect Regulation. In pharmaceutical and life sciences construction, compliance is non-negotiable. Prefabrication does not remove regulatory scrutiny. It demands earlier coordination and stronger documentation. Inspectors and agencies must be brought in as partners, not treated as obstacles. Not Everything Should Be Modular. Full building modular has not consistently succeeded in highly regulated environments. Prefabrication often works best in repeatable components such as utility racks, panels, and cleanroom assemblies. Industrialized construction is not all or nothing. Strategic application matters. Time to Market Changes the Equation. In pharmaceutical manufacturing, delayed production can mean millions of dollars per day. That reality shifts the conversation from cost savings to schedule certainty and risk mitigation. Prefabrication becomes a strategic lever for accelerating capacity while maintaining compliance.   More Resources   Thanks for listening! Please be sure to leave a rating and/or review and follow up our social accounts. Bridging the Gap Website Bridging the Gap LinkedIn Bridging the Gap Instagram Bridging the Gap YouTube Todd's LinkedIn David's LinkedIn Verista's Website   Thank you to our sponsors! Graitec North America Graitec North America LinkedIn Autodesk's Website  

America Out Loud PULSE with Dr. Vaughn & Dr. Tankersley – Of the 25 top industries in the country, recent polls now have PHARMA as 24th and the healthcare industry as 23rd, both barely exceeding the federal government at the bottom of the list. The solution to almost all of these issues is always the same- returning to a foundational trust in the eternal truths...

Pirouette Pharma CEO Conor Cullinane returns to Inside Startup Investing to share the company's progress since its last Wefunder raise—spanning FDA engagement, IND planning, and major steps toward scalable manufacturing. Pirouette is building a disc-shaped, push-button delivery system for injectable medications—aiming to turn the “violent, error-prone” experience of legacy auto-injectors into something closer to the Staples Easy Button: push once, and the device handles the rest. Chris and Conor discuss why intimidation and usability are major barriers in today's injection landscape, how Pirouette is approaching OTC naloxone via a combination-product regulatory pathway, what a pharmacokinetic study looks like, and why Pirouette is investing in manufacturing capacity to support both commercialization and pharma partnerships.   Chapters  00:44 What Pirouette is building 03:42 Progress since last raise 06:26 FDA pathway explained 09:08 PK study + size/cost/timeline 13:07 Partnerships vs. standalone commercialization 16:15 Revenue timing + adoption expectations 20:12 Manufacturing scale plan 23:34 Founder “why” 26:07 Investor close

Since podcasting came into existence in the mid-2000s, the space has become increasingly popular, remarkably lucrative and unquestionably saturated. Still, despite the countless millions of podcasts out there, countless millions of people tune in every hour of every day for conversations about every topic – including healthcare.  Joining a world occupied by This Past Weekend, Good Hang and The MM+M Podcast is The Persistence Lab. Launched by AbbVie's corporate affairs team, The Persistence Lab is the pharma giant's 10-episode project to highlight the work undertaken by its researchers, the clinical expertise of HCPs as well as the lived experiences of patients.  The first episode of The Persistence Lab was released late last week and is available wherever you listen to your podcasts.Molly James-Lundak, VP of R&D communications at AbbVie, joined me for a slightly meta conversation about joining the podcast sphere, how the drugmaker brought the idea to life and why it was important to engage with audio content creation.   And for our Trends segment, we're talking about AI in healthcare: Including the tools that actually work, the regulations on the way and the concerns that never go away.  Music: “Deep Reflection” by DP and Triple Scoop Music.   Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

AI capability has never been higher, yet most pharma AI programmes are still failing to create measurable business impact. In this solo episode, Dr Andree Bates breaks down why many pharma and biotech AI strategies are “broken before they even begin” and what a real AI strategic blueprint needs to include if you want adoption, scale, and outcomes, not just impressive pilots.Dr Andree explains the core paradox: AI can now synthesise literature at speed, accelerate discovery, and outperform human experts in specific tasks, but the business results are often disappointing because the failure is rarely technical. It is strategic. She describes the “technical obsession trap”, where organisations spend months optimising models and benchmarking competitors while adoption remains low and teams are not operationally ready to act on the outputs.She outlines three common failure modes:Innovation Theatre, where disconnected pilots never compound into enterprise valueCompetitor benchmarking, where companies copy use cases that do not fit their contextTechnology first strategy, where tools are bought before priorities are definedFrom there, she maps what a strong pharma AI blueprint must cover: grounding in business objectives, end to end deployment architecture (data, governance, capability, change), leadership and culture, rigorous financial modelling tied to revenue and ROI, and alignment across functions including commercial, medical, regulatory, R&D, market access, insights, and tech teams.Dr Andree closes with a clear challenge for leadership: competitive advantage will come to organisations that build the most intelligent operating model around AI, not those with the biggest budgets. She also offers a 45 minute AI strategic diagnostic for pharma and biotech leaders who want an honest read on what to fix before investing further.Topics CoveredWhy pharma AI impact often disappoints despite powerful toolsThe “technical obsession trap” and the AI strategy blind spotInnovation Theatre, competitor benchmarking, and technology first mistakesWhat a pharma AI strategic blueprint must includeGovernance as a foundation for scale and regulatory trustLeadership, culture, and adoption as the real differentiatorsFinancial modelling and prioritisation based on ROI and revenue impactOrganisational alignment across the full pharma value chainChoosing the right advisory partner and avoiding generic frameworksWhy strategy must come before technology to build durable advantageAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharmaceutical packaging is undergoing rapid transformation as connectivity, sustainability, automation, and evolving regulatory demands reshape how medicines are protected, tracked, and delivered. From smart packaging features and prefilled injectables to e-commerce fulfillment and digital compliance systems, packaging and equipment investment decisions are increasingly tied to flexibility, data visibility, and long-term modernization. In this episode of Off Script, we spoke with Rebecca Marquez, director of custom research at PMMI, about the association's latest Trends and Challenges in Pharmaceutical Manufacturing white paper. The conversation explores how connected packaging technologies are strengthening relationships between manufacturers, regulators, and patients; why sustainability initiatives are advancing despite material performance and validation challenges; and how growth in biologics and prefilled injectables is driving new packaging and equipment demands. Marquez also breaks down the regulatory documentation gap between OEMs and end users, the rise of automation technologies, and more.

Can D1 competitive mindset help you dominate the medical sales industry?In this episode of the Medical Sales U Podcast, I sit down with Justin Kershaw—former Michigan State player turned top-tier Spine Endoscopy Rep for Arthrex. Justin pulls back the curtain on how he transitioned from the locker room to the Operating Room, the reality of working for a $5B company like Arthrex, and why being a "Girl Dad" and a man of faith is what actually fuels his professional drive.In this episode, you'll learn: * The "3 Gatekeepers" you must win over to close deals in any hospital.* Why Arthrex uses an "Agency" model vs. traditional distributorships. * How to maintain high-level physical and spiritual discipline in a high-stress career. * Tactical advice for career pivots (how Dave broke into sales at age 35!).

In this episode of The Empowered Team Podcast, host Kari Schneider sits down with powerhouse leader Erica Sinner — multi 8-figure founder of Directory, CEO, and bestselling author of Pets Are Family. Erica's mission? Revolutionizing leadership with empathy, operational compassion, and high-performance culture that doesn't burn people out.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of these industries, exploring significant regulatory shifts, scientific breakthroughs, and strategic corporate maneuvers that are shaping the future of healthcare.The pharmaceutical and biotech sectors are currently navigating a period of profound transition. Recent regulatory developments have captured attention, particularly the U.S. Supreme Court's decision to overturn emergency tariffs imposed by the previous administration. This ruling is pivotal as it alleviates financial pressures on the industry, allowing companies to redirect their resources towards innovation and development. It underscores the interconnectedness of global supply chains and highlights the importance of stable regulatory environments for fostering industry growth.In a notable advancement within oncology, AstraZeneca has achieved FDA approval for its combination therapy of Calquence and Venclexta as an all-oral regimen for first-line chronic lymphocytic leukemia (CLL). This approval not only positions AstraZeneca competitively in the BTK inhibitor market but also signifies a shift towards more patient-friendly treatment regimens. By simplifying therapy, this development promises to enhance patient compliance and improve outcomes, challenging existing standards in CLL care.Meanwhile, internal challenges at the Centers for Disease Control and Prevention have led to a postponement of a critical vaccine advisory panel meeting. This delay occurs amid evolving vaccine policies that have sparked debate within the public health community, potentially impacting immunization strategies and initiatives aimed at bolstering public health.Corporate governance within the industry is also experiencing shifts. Novo Nordisk has nominated two industry veterans to its board as part of an ongoing strategy to align leadership with evolving business objectives. Similarly, Roche is contemplating divesting its once-blockbuster antibiotic Rocephin in response to competitive pressures from generics in Europe. These moves reflect a broader industry trend where companies are re-evaluating their portfolios to better respond to market dynamics and patent expirations.Novartis is making strategic changes as well by selling its stake in Novartis India Limited while maintaining separate commercial and R&D interests in the region. This action highlights a growing trend among pharmaceutical giants towards streamlining operations and focusing on high-growth areas—a strategy aimed at maximizing resource allocation efficiency.Despite narrowly missing a $1 billion revenue target for 2025, Madrigal Pharmaceuticals remains optimistic about the growth prospects of its drug Rezdiifra within the metabolic dysfunction-associated steatohepatitis (MASH) market. The company anticipates further expansion driven by unmet medical needs, underscoring the competitive dynamics within this therapeutic area.In personnel movements that could influence strategic directions, Daiichi Sankyo has appointed former Novartis CMO John Tsai as head of its R&D division. His expertise is expected to bolster Daiichi's focus on oncology and other critical therapeutic areas, potentially accelerating innovation within their drug development pipeline.Meanwhile, Manus Bio has secured a $15 million contract with the U.S. government for domestic supply of shikimic acid, an essential component for producing Tamiflu. This contract highlights efforts to strengthen domestic pharmaceutical supply chains amid global uncertainties—a crucial consideration for ensuring medication availability during crises.In clinical research, a setback was observed with Grail's Galleri cancer blood test trial failing to meet its primary endpoint in collaboration with the NHS. The resulting decline in GrailSupport the show

The European Commission has called for Washington to abide by the terms of the trade deal struck last year with the EU. This comes after US President Donald Trump announced new global tariff hikes a day after an adverse Supreme Court ruling. All to discuss with Dan Mulhall Former Ambassador of Ireland to the United States.

Dans cet épisode spécial de Cheminements, enregistré en live devant un public, nous plongeons au cœur d'une collaboration réussie qui dépasse le simple cadre du mécénat. Comment un grand laboratoire industriel et une association de terrain parviennent-ils à co-construire des solutions concrètes pour les patientes ? À travers deux projets phares, la caravane itinérante "COCON" et le forum "COLIBRIDGE", nos invitées dévoilent les coulisses d'un partenariat fondé sur la confiance, la transparence et une ambition commune : rompre l'isolement face aux cancers gynécologiques et transformer durablement l'accès aux soins de support.Les intervenantes :Coralie Marjollet : présidente d'IMAGYN, association qui représente et accompagne les femmes touchées par des cancers gynécologiques.Mouna Champain : vice-présidente et Directrice Médicale France chez GSK.Les sujets abordés dans l'épisode :La genèse de la collaboration entre GSK et Imagine durant le premier confinement.Le projet COCON : une caravane itinérante pour aller à la rencontre des patientes sur tout le territoire et lever les tabous sur les cancers dits "du rez-de-chaussée".L'importance des soins de support et de la libération de la parole sur des sujets comme la sexualité ou la nutrition.Le forum COLIBRIDGE : un espace de partage et de solidarité entre différentes associations de patients en oncologie.Les valeurs non négociables d'un partenariat industrie-association : transparence, éthique, loyauté et vision à long terme.Le passage d'un soutien ponctuel à une relation de "coéquipiers" pour peser auprès des institutionnels.Crédits :Écriture : Marguerite de RodellecProduction : MedShake StudioCet épisode à été enregistré durant la première édition de la Journée Patients & Pharma, un événement pour créer un véritable espace de dialogue entre représentants de patients et industrie qui a eu lieu le 4 décembre 2025, à la Maison A. Trocadéro. Chers auditeurs, je vous informe que d'autres épisodes exclusifs du podcast Cheminements ont été enregistrés en direct, pour donner la parole à des binômes patients / laboratoires qui sont venus raconter leurs collaborations, leurs défis, et parfois même… leurs histoires d'amour professionnelles. Alors si ce sujet vous parle, rejoignez-nous.Ressources :https://patientspharma.com/En ouvrant le dictionnaire, on apprend que "cheminement" désigne une progression graduelle, un mouvement, une avance graduelle.➡ Retrouvez tous les épisodes sur https://www.cheminements.co/❤️ Soutenez-nous gratuitement :Abonnez-vous !Laissez 5 étoiles et un avis sur Apple Podcasts ou Spotify ⭐Cheminements, le podcast santé des femmes, dans vos oreilles chaque semaine.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

    Slam The Gavel welcomes back Andrea Brewer to the podcast. Today she discussed how the states are handling a person's gender on their birth certificate from the date of birth. Andrea went over some of the states that have administrative processes and the statistics of some of the states where there is no court order required, and how many states allow for a change of gender just on a simple affidavit. The VS42 form was discussed as well as it appears anyone can put information on this document for gender.    Also was discussed Debbie Carroll's contribution to the book Raised By These Wolves, Family and Juvenile Courts Continue to Destroy Future Generations, which involved the Memorandum of Procedure.To Reach Andrea Brewer:  oceandesignzart@gmail.comSupportshow(https://www.buymeacoffee.com/maryannpetri)Maryann Petri: dismantlingfamilycourtcorruption.comhttps://www.tiktok.com/@maryannpetriFacebook:  https://youtube.com/@slamthegavelpodcast?si=INW9XaTyprKsaDklhttps://substack.com/@maryannpetri?r=kd7n6&utm_medium=iosInstagram: https://www.instagram.com/guitarpeace/Pinterest: Slam The Gavel Podcast/@guitarpeaceLinkedIn: https://www.linkedin.com/in/maryann-petri-62a46b1ab/  Twitter https://x.com/PetriMaryannEzlegalsuit.com   https://ko-fi.com/maryannpetrihttps://www.zazzle.com/store/slam_the_gavel/aboout*DISCLAIMER* The use of this information is at the viewer/user's own risk. Content on this podcast does not constitute legal, financial, medical or any other professional advice. Viewer/user/guest should consult with the relevant professionals. IRS CIRCULAR 230 DISCLOSURE: To ensure compliance with requirements imposed by the Internal Revenue Service, we inform you that any U.S. federal tax advice contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of (1) avoiding penalties under the Internal Revenue Code or (2) promoting, marketing or recommending to another party any transaction or matter addressed herein. Reproduction, distribution, performing, publicly displaying and making a derivative of the work is explicitly prohibited without permission from content creator. The content creator maintains the exclusive copyright and any unauthorized copyright usage is strictly prohibited.  Podcast is protected by owner from duplication, reproduction, distribution, making a derivative of the work or by owner displaying the podcast. Owner shall be held harmless and indemnified from any and all legal liability.Support the showSupportshow(https://www.buymeacoffee.com/maryannpetri)http://www.dismantlingfamilycourtcorruption.com/

TODAY ON THE ROBERT SCOTT BELL SHOW: Jonathan Emord, Pharma Attacks RFK Jr., FDA Moderna Reversal, MAHA Midterm Strategy, Voter ID, Hawaii's Emergency Power Grab, Ari Whitten, Red Light Therapy, Inflammation Reduction, Anhalonium Lewinii, and MORE! https://robertscottbell.com/jonathan-emord-pharma-funded-attacks-on-rfk-jr-fdas-moderna-reversal-maha-midterm-strategy-voter-id-hawaiis-emergency-power-grab-anhalonium-lewinii-and-more/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the industry landscape, from scientific breakthroughs to regulatory shifts and strategic corporate maneuvers.Let's start with Insmed's Brinsupri, a newly approved respiratory therapy that has captured attention with its projected $1 billion in sales by 2026. This ambitious forecast is grounded in Brinsupri's robust clinical efficacy and the increasing demand for innovative respiratory treatments. This development reflects a broader industry trend where targeted therapies are not only improving patient outcomes but also driving significant revenue growth. As respiratory conditions continue to be a major health challenge globally, the success of therapies like Brinsupri underscores the potential for innovation to meet these critical needs.In parallel, Merck is working strategically with its RSV antibody, Enflonsia, seeking a second-season approval to bolster its competitive stance against Sanofi and AstraZeneca's Beyfortus. The race in infant RSV prevention is intense as companies vie to establish dominance in this crucial segment of infectious disease management. Merck's efforts highlight the broader push within the industry to develop preventive measures that could significantly alter public health landscapes by reducing the incidence of severe respiratory illnesses in vulnerable populations.Meanwhile, regulatory scrutiny remains a constant for pharmaceutical companies. The FDA's recent review of Johnson & Johnson's advertising for Tremfya, targeting ulcerative colitis, emphasizes the agency's commitment to ensuring that efficacy claims are both truthful and transparent. This serves as a reminder of the importance of maintaining regulatory compliance and ethical advertising practices within the industry—a critical aspect as companies navigate complex marketing landscapes while ensuring patient trust.Shifts in leadership within key health organizations are also noteworthy. Jay Bhattacharya stepping into the role of acting CDC chief after Jim O'Neill's departure could signal changes in public health policy and research priorities. Such transitions can have profound effects on how emerging health challenges are addressed, potentially influencing everything from vaccine distribution strategies to research funding allocations.As we turn to policy discussions, President Donald Trump's most favored nation drug pricing proposal continues to stir debate. This initiative aims to lower drug prices by benchmarking them against international rates, but it faces resistance from free-market advocates who argue it could stifle pharmaceutical innovation. The ongoing discussion around drug pricing reform is pivotal, as it impacts both patient access to medications and the incentives for companies to invest in new drug development.Strategic realignments in the contract development and manufacturing organization (CDMO) sector are also making headlines. Recipharm's sale of its Israeli API plant to Scinai Immunotherapeutics, alongside a new CDMO partnership, illustrates how companies are optimizing resources to focus on core competencies and expand service offerings. This strategic shift highlights the dynamic nature of CDMOs as they adapt to changing market demands and technological advancements.In Alzheimer's research, there's promising news with a study suggesting that a blood test could predict when symptoms will appear, representing a significant leap forward in early diagnosis and intervention strategies. These advancements offer hope for altering the treatment landscape of neurodegenerative diseases through timely therapeutic interventions that could improve quality of life for patients. However, challenges remain as seen with Johnson & Johnson pausing enrollment in itsSupport the show

In Part 2 of the 2026 pharma forecast, the guests discuss the biggest unknowns for the year ahead and share a personal goal they're working towards in 2026. Speaker bios Dheepa Chari Vice President and Head of Global Scientific Communications, GSK Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered. Emma Charles Senior Vice President of European Markets, BMS Emma oversees Bristol Myers Squibb's operations across 19 countries of Europe, bringing extensive global leadership experience spanning Europe, Asia, Latin America and the Middle East. Yacin Marzouki  Omnichannel expert Within the pharmaceutical sector, Yacin specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution. Mary Stutts CEO, Healthcare Businesswomen's Association Mary leads a global organisation that advances representative leadership, strengthens the talent pipeline for healthcare and life sciences, and fuels business growth across the sector.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a wide array of topics, from groundbreaking therapies and strategic corporate moves to regulatory shifts and industry trends shaping the future of healthcare.We begin with Eli Lilly, which is making significant strides with its combined Zepbound and Taltz therapy, showing promising results in the treatment of psoriasis and obesity. This combination therapy, initially successful in psoriatic arthritis, is set to transform treatment protocols by bridging gaps between psoriasis and obesity. This dual-targeting approach highlights a burgeoning trend in the industry: the use of combination therapies to enhance patient outcomes while streamlining treatment regimens. This strategy not only promises better management of interconnected conditions but also reflects a broader industry goal of maximizing therapeutic reach with existing drugs.Novartis is advancing its portfolio with the oral BTK inhibitor, Rhapsido, following a successful Phase 3 trial for a new chronic hives subtype. This development underscores Novartis's commitment to addressing niche markets and unmet medical needs, emphasizing the pharmaceutical industry's focus on expanding the utility of existing drugs. Additionally, Novartis has entered into a notable partnership with Macrocycle Biotech for cardiovascular drug development. This collaboration represents a broader trend where large pharmaceutical companies seek innovative partnerships to expand their therapeutic portfolios through cutting-edge biotech solutions.Meanwhile, Moderna's influenza vaccine submission has been accepted by the FDA after an initial rejection, illustrating a responsive regulatory environment crucial for timely access to vaccines amid potential flu outbreaks.Johnson & Johnson's $1 billion investment plan in the U.S., focusing on cell therapy, aligns with broader industry trends towards personalized medicine and advanced therapeutic approaches. This investment is part of a strategic pivot towards cell and gene therapies that promise to redefine treatment pathways for complex diseases. Similarly, Bayer's $7.25 billion settlement over Roundup litigation shows an industry keen on resolving legal challenges swiftly to refocus efforts on innovation.Regulatory reforms are also gaining attention, with proposals aimed at streamlining FDA processes to enhance drug access and reduce burdens. These reforms could significantly impact drug development timelines and market entry strategies, reflecting an ongoing discourse on balancing regulation with fostering innovation.On a global scale, Stada's €85 million investment in Saudi Arabia points to a strategic move towards enhancing supply chain resilience in the Middle East and North Africa. This aligns with industry trends focusing on regional manufacturing capabilities to ensure drug availability while reducing logistical complexities.A notable example of strategic resource allocation is Eli Lilly's $100 million upfront payment for CSL's IL-6 antibody development rights. This reflects an adaptive approach where initial clinical setbacks are seen as opportunities for new therapeutic ventures rather than dead ends.Turning our attention to Alzheimer's research, Korsana Biosciences has emerged from stealth mode with substantial funding aimed at developing an anti-amyloid antibody capable of crossing the blood-brain barrier. This effort addresses a critical need within Alzheimer's disease treatment—a field marked by intense competition and scientific challenge. Parallelly, IQVIA Biotech highlights the importance of accelerating early-stage interventions for Alzheimer's through data analytics and optimized clinical trials. Such efforts aim to expedite regulatory approvals and bring new therapies to market faster—a trend indicative of leveragSupport the show

In this episode, Dr. Kahina Lang, Executive Director and Head of Next Gen Drug Delivery at Merck Group, discusses her pioneering work developing targeted mRNA delivery systems using lipid nanoparticle (LNP) technology. She shares insights on building an internal startup within the world's oldest pharmaceutical corporation, the technical innovations enabling precision medicine, and the future of cell and gene therapies. Tune in for an insightful conversation on how entrepreneurial leadership, digital-first research approaches, and open-innovation models are accelerating breakthrough therapeutics from the lab to the clinic.

Yes, headlines say U.S. life expectancy has rebounded. But here's what they don't tell you. The United States ranks 32 out of 38 developed nations in life expectancy according to OECD data.Thirty-second. Out of thirty-eight. That places America near the bottom of the developed world behind Turkey, Estonia, the Czech Republic, and the Slovak Republic. Only six developed nations rank lower.At the same time:• In 2024, the 10 largest pharmaceutical companies reported more than $100 billion in profits**• The industry spent over $5 billion on television advertising• Prescription drug commercials account for a significant share of evening news ads• The U.S. healthcare system remains structured around treatment, not prevention• Ultra-processed foods dominate the American dietThe United States spends more per capita on healthcare than any other developed nation.Yet we rank near the bottom in longevity. Americans deserve the complete story — not just the comfortable headline. Source: U.S. Senate Committee on Health, Education, Labor and PensionsThank you to our sponsor: Preserve Gold - text "ASK PHIL" to 50505 and go to https://DrPhilGold.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This job market needs a different approach - tune in to hear why. If you've been applying to roles, asking for promotions, taking on stretch work, and getting ghosted or hearing “not yet” or “there's no budget,” this conversation is for you.When budgets tighten and leaders become selective, performance alone isn't enough. In these environments, they don't promote or hire “good enough.” They move toward the person who feels necessary. And when the rules aren't clear, it's easy to internalize stalled growth as a personal failure instead of a strategic gap.So I'm also going to share the insider conversations that happen behind closed doors of leadership meetings.In this episode, you'll learn:Why performance reviews and stretch assignments don't automatically lead to advancementWhat talent conversations actually focus on behind closed doorsHow lack of clarity gets exposed quickly in a tight marketWhy perception and positioning matter as much as credentialsDetails about my book releasing February 24th - Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech.If you've been wondering why it feels harder than it should, this episode will help you see what's really happening—and what to think about differently.Book Waitlist: My book is available February 24th! Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech join the waitlist here. Are you a woman in Pharma/Biotech who wants to improve her career? Learn more and apply to work with me here. Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

In this episode, Donna and Tom sit down with Elena Polansky, Founder of Somerset Solutions Advisory Partners and former Chief Procurement Officer and Vice President of Global Sourcing & Procurement at BioMarin Pharmaceutical, to explore the evolution of procurement from a support function to a strategic value-engine. Elena shares insights from her 25-year career, including over 20 years at Pfizer where she delivered more than $1 billion in cumulative savings. She discusses navigating hidden costs in global sourcing, from geopolitical volatility to regulatory complexities, and the unique procurement challenges within life sciences. Elena also emphasizes the power of curiosity, asking smart questions, and staying open to feedback as essential traits for success in today's dynamic supply chain landscape. Takeaways: Procurement's transformation into a strategic business driver Managing hidden costs and risks in global pharmaceutical sourcing The role of innovation and technology in modern procurement The importance of curiosity and continuous learning Stay connected with CSCR on LinkedIn (Center for Supply Chain Research) and Instagram (@pennstatesupplychain), and be sure to follow us on Spotify, Apple Podcasts, or wherever you are tuning into Unpacked: Insights hosted by the Penn State Smeal Center for Supply Chain Research™. Thank you for joining us!  Visit our website: https://www.smeal.psu.edu/cscr  Guest Bio: Elena Polansky is a results-driven executive and strategic advisor with more than two decades of experience transforming procurement, operations, and organizational culture across global enterprises. As the Founder of Somerset Solutions Advisory Partners, she focuses on unlocking value through procurement transformation, supplier ecosystem optimization, and strategic advisory support. Her work centers on helping organizations evolve with clarity, confidence, and measurable impact. Before launching Somerset Solutions, Elena served as Chief Procurement Officer and Vice President of Global Sourcing & Procurement at BioMarin Pharmaceutical, where she established a centralized global sourcing function. Under her leadership, the team harmonized tools and processes, strengthened sourcing capabilities, and exceeded savings targets. Elena spent 20 years at Pfizer, advancing through multiple senior leadership roles in Global Sourcing and Global Supply. She delivered more than $1 billion in cumulative savings across direct and indirect categories and led the Internal Medicines External Supply organization, overseeing a global network of 50+ contract manufacturers producing 1,500+ SKUs. Her leadership ensured supply continuity, quality, and agility across diverse and highly regulated supply ecosystems. Elena began her career in consulting, leading strategy development, technology implementations, and change management initiatives for clients in the manufacturing and distribution sectors. At Andersen, she executed ERP implementations and software selection engagements; at Proxicom, she shaped digital strategy for a global bank and led the design of an internal knowledge management platform that improved collaboration and firm-wide efficiency. Elena is a proud Penn State alumna, holding a BS in Business Logistics and International Business from the Smeal College of Business. She resides in New Jersey with her husband—also a Penn State graduate—their two children, and their two dogs.

On today's episode, we take a trip back to 1966 – when MM+M was born.A fledgling newsletter focused on pharma advertising, MM+M has since grown into an award-winning publication with digital elements like our website – mmm-online.com – our social media platforms and even this podcast you're listening to.To walk us through the brand's beginnings in a small office in southwestern Connecticut to its acquisition by David Gideon in the early 1980s – is Adam Arnegger, executive director of investment at WPP Media.Adam is not only an adland vet of over 25 years, he's also the grandson of Captain Jack Sullivan, who founded MM+M in 1966.He recently came to our office in Chelsea for a conversation centered around the brand's diamond anniversary, his grandfather's vision for the publication and the Captain Jack Sullivan Founder Award that will be presented at the 2026 MM+M Awards ceremony in October.As for our Trends segment, we're talking about the increasing silliness of the ongoing FDA warning letter spree. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

As 2026 gets underway, healthcare and life sciences face a year of both promise and pressure, with investment, innovation and equity all in sharp focus. In Part 1 of this year's pharma forecast, four leaders explore where real opportunity lies, from health investment to personalisation and women's health, alongside the key threats that could slow progress.  Speaker bios Dheepa Chari Vice President and Head of Global Scientific Communications, GSK Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered. Emma Charles Senior Vice President of European Markets, BMS Emma oversees BMS operations across 19 countries, bringing extensive global leadership experience spanning Europe, Asia, Latin America and the Middle East. Mary Stutts CEO, Healthcare Businesswomen's Association Mary leads a global organisation advancing the impact of women in healthcare, and is a prominent advocate for inclusive leadership, representative workforces and health equity.

My newsletter: https://simonowens.substack.com/   For decades, Diane Salvatore helped lead some of America's most recognizable magazine brands, including Consumer Reports, where rigorous product testing and consumer safety were core to the mission. Now, as executive director of the MedShadow Foundation, she's applying that same watchdog mentality to one of the most opaque corners of the marketplace: prescription and over-the-counter drugs.    In a recent interview, Diane walked through how MedShadow operates as a nonprofit investigative newsroom, its expansion into social media video, and its plan to build a donor-supported model that funds independent health journalism.

This week, Daire Cregg and Sarah McIntosh speak with Matthew Ryan, a native of Thurles in county Tipperary.Matthew is a graduate of UCD Dairy Business and currently works as AgTech and Pharma sales manager with the Irish Farmers Journal.Alongside his job Matthew is heavily involved in the running of the home farm, where they rear calves and keep some thoroughbred horses.In the interview he shares his journey to get where he is today, some of the upsides and downsides to his role and what his day to day consists of.He also shares some aspects of his life outside of the job, including a recently developed grá for long-distance running. Hosted on Acast. See acast.com/privacy for more information.

Dans cet épisode de Cheminements, nous plongeons au cœur de l'urgence absolue : la méningite. Cette infection foudroyante, qui peut toucher n'importe qui sans prévenir, impose une course contre la montre où le diagnostic précoce est la seule clé pour éviter le décès ou des séquelles irréversibles. À travers le récit bouleversant d'une mère devenue présidente d'association et l'expertise d'un infectiologue, nous explorons comment la collaboration entre patients et soignants sauve des vies et comment les nouvelles technologies diagnostiques transforment la prise en charge à l'hôpital.Les intervenants :Patricia Merhant-Sorel : Présidente de l'association Petit Ange (Ensemble contre la méningite). Après avoir perdu sa fille Gwendoline en 2003, elle consacre son action à l'accompagnement des familles et à la sensibilisation du public et des professionnels de santé.Docteur Nicolas Ettahar : Infectiologue au Centre Hospitalier de Valenciennes. Expert de la réalité clinique des maladies infectieuses, il apporte son regard sur les enjeux de diagnostic et de prévention.Les sujets abordés dans l'épisode :Le témoignage de Patricia sur la perte brutale de sa fille et la création de l'association Petit Ange.Les formes fulgurantes de la maladie : pourquoi l'évolution peut être fatale en moins de 12 heures.L'importance capitale du diagnostic différentiel face à des symptômes parfois trompeurs (fièvre, maux de tête).L'apport des tests rapides (PCR) pour cibler immédiatement le bon traitement antibiotique.Le rôle de la vaccination et des mesures barrières dans la prévention collective.La nécessité d'un dialogue permanent entre les familles, les cliniciens et les industriels du diagnostic.Écriture : Marguerite de RodellecProduction : MedShake StudioCet épisode est enregistré dans le cadre de la première édition de la Journée Patients & Pharma, un événement pour créer un véritable espace de dialogue entre représentants de patients et industrie qui aura lieu le 4 décembre 2025, à la Maison A. Trocadéro. Chers auditeurs, je vous informe que cette journée s'écoutera aussi ! Des épisodes exclusifs du podcast Cheminements seront enregistrés en direct, pour donner la parole à des binômes patients / laboratoires qui viendront raconter leurs collaborations, leurs défis, et parfois même… leurs histoires d'amour professionnelles. Alors si ce sujet vous parle, rejoignez-nous.Ressources :https://patientspharma.com/En ouvrant le dictionnaire, on apprend que "cheminement" désigne une progression graduelle, un mouvement, une avance graduelle.➡ Retrouvez tous les épisodes sur https://www.cheminements.co/❤️ Soutenez-nous gratuitement :Abonnez-vous !Laissez 5 étoiles et un avis sur Apple Podcasts ou Spotify ⭐Cheminements, le podcast santé des femmes, dans vos oreilles chaque semaine.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of significant shifts in the industry, marked by leadership changes, scientific advancements, strategic partnerships, and regulatory challenges.Starting with Sanofi, a notable leadership transition has taken place as Paul Hudson steps down from his role as CEO. Belen Garijo from Merck KGaA has stepped into this pivotal role. Her appointment is part of a broader industry trend toward diversifying leadership, especially with more women leading top-tier pharmaceutical companies. The implications of this shift could be profound for Sanofi, potentially stabilizing its operations and revitalizing its research pipeline. Stakeholders are keenly observing how this new leadership might steer Sanofi through complex market dynamics.In regulatory news, Moderna has encountered a significant hurdle with the FDA declining to review its next-generation mRNA flu vaccine. This decision has sparked an ongoing public dialogue between Moderna and U.S. health regulators, underscoring the complexities involved in navigating regulatory pathways for novel mRNA technologies beyond their initial success with COVID-19 vaccines. The Department of Health and Human Services has supported the FDA's decision, emphasizing the critical importance of meticulous scrutiny when it comes to new vaccine platforms. This development highlights the challenges biotech companies face in ensuring compliance with stringent regulatory standards.Financial updates reveal CSL experiencing a sharp decline in net profits, dropping from $2 billion to $384 million year-over-year. This financial downturn has been linked to strategic missteps or operational inefficiencies within the company, prompting a change in leadership. Such shifts reflect broader challenges faced by companies within the biotech sector as they strive to maintain financial stability amid fluctuating market conditions.In contrast, Alnylam Pharmaceuticals has reported its first profitable year despite underwhelming sales figures for its drug Amvuttra in the ATTR-CM market. This milestone is significant for Alnylam as it demonstrates resilience and the potential to pivot successfully amidst market uncertainties. However, the company will need to remain vigilant about revenue streams and market dynamics moving forward.Turning to advertising strategies, Johnson & Johnson's Tremfya continues to buck industry trends by maintaining a strong presence in television advertising through 2026. This strategy is noteworthy given the general decline in traditional media spending across the industry. J&J's commitment highlights its determination to sustain market share against competitors such as AbbVie's Rinvoq and Skyrizi.On the strategic front, Takeda Pharmaceuticals is consolidating its U.S. operations by reducing its Boston presence. By subleasing over 630,000 square feet of office space, Takeda aims to streamline operations and concentrate resources on key development projects at its new Cambridge hub. This move reflects broader industry trends towards operational efficiency and resource optimization.In clinical advancements, BridgeBio has reached a promising milestone with successful Phase 3 trial results for infigratinib in treating dwarfism. This breakthrough offers new therapeutic options for children affected by this condition and exemplifies ongoing innovations in genetic medicine. The success of this trial positions BridgeBio on a path toward regulatory approval, potentially transforming care for patients with limited treatment options.Agilent has achieved FDA approval for its companion diagnostic test alongside Merck's Keytruda for ovarian cancer treatment. This approval highlights the growing importance of precision medicine in oncology, where tailored treatments based on individual paSupport the show

In this episode of Disruption/Interruption, KJ sits down with Julian Circo, Co-Founder of Hyfe, a company revolutionizing respiratory health diagnostics through AI-powered cough monitoring. Julian shares his unconventional journey from humanitarian work in post-conflict zones to building the world's largest cough dataset—over 700 million samples. The conversation explores how Hyfe is transforming coughing from a subjective symptom into an objective, quantifiable biomarker, enabling better research, drug development, and patient care. Julian discusses the challenges of disrupting the conservative pharmaceutical industry, the surprising complexity of measuring coughs, and Hyfe's groundbreaking digital therapeutic for chronic cough sufferers. Four Key Takeaways [0:41] Coughing is Medicine's Most Common Yet Least Understood Symptom - Despite being the single most common symptom in medicine for over a century, medical science still cannot answer basic questions like "what is a normal amount of coughing for a healthy person?" Even top pulmonologists disagree significantly on this fundamental question. [11:27] Building the World's Largest Cough Dataset Required Creative Problem-Solving - Hyfe collected over 700 million cough samples by launching a free consumer app during COVID-19 that monitored coughs in the background. This approach solved the critical challenge of gathering diverse, real-world data across different demographics, environments, and microphones—essential for training accurate AI models. [21:52] Pharma's Resistance to Disruption is Actually Rational - The pharmaceutical industry's notorious resistance to innovation stems from legitimate needs: trials spanning months or years require consistent measurement methods to compare data over time. Hyfe succeeded by "leading with science" rather than pitching disruption, focusing on the measurable value they create. [27:30] A Digital Therapeutic Offers Hope Where 15 Drug Trials Failed - Over the past 13 years, 15 pharmaceutical molecules for chronic cough treatment have failed clinical trials. Hyfe is developing a digital therapeutic based on behavioral cough suppression therapy—similar to physical therapy for joints—that has already shown 40% efficacy in preliminary research, offering hope to the one in ten Americans suffering from chronic cough. Quote of the Show (4:28):"People innovate as a way of life. It’s not a luxury. You have to find ways to communicate. You have to find ways to access goods. You have to find ways to make do…” – Julian Circo Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Julian Circo: LinkedIn: https://www.linkedin.com/in/icirco/Company Website: https://www.hyfe.com/Failed Chronic Cough Candidates: https://support.hyfe.com/hubfs/HTML/failed_antitussives_timeline.htmlCoughPro: https://coughpro.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Alan Cassels reveals how pharma creates disease markets and spins stats to make marginal drugs look life-saving. #PharmaMarketing #DrugOveruse #HealthPolicy #HealthTalks

A record number of viewers tuned in, but did they spend? We will analyze the "Dorito Index" and what the Super Bowl ad lineup—dominated by Tech and Pharma—tells us about the health of the consumer.Today's Stocks & Topics: Centene Corporation (CNC), Market Wrap, Robinhood Markets, Inc. (HOOD), Stock Valuation, The "Super Bowl" Consumer Hangover, Bio-Techne Corporation (TECH), MSC Industrial Direct Co., Inc. (MSM), VICI Properties Inc. (VICI), iShares MSCI Japan Value ETF (EWJV), Franklin FTSE South Korea ETF (FLKR), Franklin FTSE Mexico ETF (FLMX), The Inflation Report, A. O. Smith Corporation (AOS), Vistra Corp. (VST), Constellation Energy Corporation (CEG), Hiring in the U.S.Our Sponsors:* Check out Quince: https://quince.com/INVESTAdvertising Inquiries: https://redcircle.com/brands

The 2026 IPO Quiz: Since January 1, 2026How many companies?20How many total founders?34How many female founders?2: Cassandra Curtis and Jennifer GarnerHow many companies have female founders?1: Once Upon a FarmHow many companies with only female founders?0Once Upon a Farm: J. Garner, J. Foraker, C. Curtis, A. RazCo-founded in 2015 by Cassandra Curtis and Ari RazIn 2017, Jennifer Garner joined as a co-founder and “Chief Brand Officer”, alongside CEO John ForakerMost represented industry?Healthcare (5), including Pharma, Biotech, and AI Biotech How many are already down from their offer price (as of 10:45am)?17How many female chairs?1: Shoushana Ohanessian: VenHub GlobalHow many female CFOs?1: Cantor Equity VI: Jane Novak (F)How many female CEOsZeroHow many directly associated with Epstein Island?1: Cantor Equity VI: Cantor was founded over 75 years ago and was led by Howard W. Lutnick from 1992 until February 2025 when he became the United States Secretary of CommerceSon Brandon G. Lutnick CEO/ChairTrump Commerce Sec. Lutnick admits visiting Epstein island during family vacationHow many boards have ZERO male directors?ZEROHow many boards of zero female directors?Only six!How many with one? Only six!How many boards with at least 30% women? 4AgomAb Therapeutics 2/6 33%Green Circle Tech 2/5 40%Once Upon a Farm 4/9 44% (CEO/Chair, CFO, Nominating Committee chair, Compensation Committee chair = MEN)VenHub GlobalTotal percentage of women?18%BONUS HEADLINES QUIZKraft Heinz pauses work to split the company as new CEO says ‘challenges are fixable'What were the two new companies?Strategic Flavor Holdings Co. and North Atlantic Provisions Co.Global Taste Elevation Co. and North American Grocery Co.North Atlantic Snack Holdings and Strategic Grocery Development GroupInternational Flavor Solutions Co. and United Continental Grocery Co.Universal Taste Logistics Co. and North American Food Alignment Co.Proxy Voting: Asset Managers Increased Their Support for Management in 2025What percentage of management resolutions did the Big Three index managers support in the 2025 proxy year? Hint, it's up 3% since 2023.99% (98.7%), up from 96% in 2023Top 10 U.S. asset managers in 2025? 98%Top 50 U.S. asset managers in 2025? 96%What percentage of shareholder resolutions did the Big Three index managers support in the 2025 proxy year? Hint, it's down 1.5%.7.5%True or False: in a landmark social media case that seeks to hold tech companies responsible for harms to children, A google lawyer said this to Jurors yesterday: “It's not social media addiction when it's not social media and it's not an addiction.”True or False: xAI cofounder Jimmy Ba, the second cofounder [Tony Wu] to depart xAI in less than 48 hours, said this yesterday: "It's time to recalibrate my gradient on the big picture. 2026 is gonna be insane and likely the busiest (and most consequential) year for the future of our species."According to a new report from the WSJ, why did OpenAI fire Executive Ryan Beiermeister?sexual discriminationWhat's the story behind the story?Ryan Beiermeister, one of OpenAI's top safety executives, a vice president leading OpenAI's product policy team, was accused of sexual discrimination against a male employee after she voiced opposition to the controversial rollout of AI erotica in its ChatGPT product saying that she opposed adult mode, worried it would have harmful effects for users, and that she believed OpenAI's mechanisms to stop child-exploitation content weren't effective enough, and that the company couldn't sufficiently wall off adult content from teens.Beiermeister started a peer-mentorship program for women at OpenAI in early 2025.

Is Artificial Intelligence actually helping cancer patients, or is it just noise? In this episode of The Patient From Hell, Samira sits down with Dr. Shadi Nabhan to separate the Hype from the Reality in 2026.We discuss the massive evolution in oncology—from the "library days" of 1995 to the AI-driven diagnostics of today. Dr. Shadi shares his "Airport Analogy" for navigating a cancer diagnosis, offers a life-changing reframe on how we view advanced disease (it's not just "curable" vs. "terminal"—it can be "controllable"), and gives his #1 piece of advice for selecting a medical team that will actually show up for you when things get hard.Key Topics Discussed:AI in 2026: How doctors use AI to simplify complex terms like CAR T-cell therapy and why patients need to "trust but verify" AI-generated medical advice.The "Controllable" Reframe: Why treating metastatic cancer like diabetes or hypertension changes the patient experience.Navigating the "Airport": Why the healthcare system feels like being dropped in a foreign airport without a map.Advice for the Industry: What Healthcare Systems and Pharma companies need to change right now regarding clinical trials and drug pricing.About Today's Guest Dr. Chadi Nabhan:Dr. Chadi Nabhan is a board-certified hematologist, oncologist, and the Chief Medical Officer at Ryght, Inc., where he leads the integration of Generative AI into clinical research to accelerate the delivery of lifesaving therapies. With a career spanning leadership roles at Caris Life Sciences and the University of Chicago, Dr. Nabhan is a prolific researcher with over 300 publications and a prominent author whose work focuses on the intersection of medicine, justice, and technology.AI Visionary: Leading the charge in using AI to optimize clinical trials and patient outcomes.Expert Clinician: Trained at Northwestern and Harvard, with decades of experience in malignant hematology.Renowned Author: Published three books with Johns Hopkins University Press, including The Cancer Journey and the forthcoming AI and Cancer Care (2026).Podcast Host: Voice of the popular weekly series Healthcare Unfiltered.Quotes from the Episode:"We cure more patients than we have ever dreamt of... Women who are affected by breast cancer today are more likely to be completely cured." "Availability is key. Are they going to really pick up the phone and talk to you when you need them?"00:00 - The reality of the cancer journey (It's not smooth sailing)01:00 - Intro: Dr. Shadi Nabhan & The Fun Factor01:25 - AI in Healthcare: Hype, Hope, and Reality04:15 - How doctors use AI to explain complex therapies06:38 - Warning for patients using AI: "Garbage in, Garbage out"08:45 - The Evolution of Medicine: 1995 vs. 202613:00 - The "Airport Analogy": Why patients feel lost17:30 - MUST WATCH: Reframing "Terminal" cancer as "Controllable"21:30 - Advice for Healthcare Leaders: Agility & Patient Involvement23:50 - Advice for Pharma: Drug Pricing & Accelerating Innovation26:00 - The #1 criteria for picking your medical team28:18 - The importance of Second Opinions28:50 - What to expect in late 2026: AI in Cancer Care Book

Drugs. They ruin lives but when you have a medicine that is supposed to help you that is a good drug. But sometimes the companies that make good drugs can make a very bad one an that is how you end up with millions of addicts and deaths. This is the story of Perdue Pharma and OxyContin Watch the ⁠⁠podcast⁠⁠ Fight me at ⁠⁠⁠⁠⁠war of the barons⁠⁠⁠⁠⁠ Travel to Croatia with me ⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠ Travel to Greece with me ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Travel to Thailand with me ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Check out our sister podcast the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Mystery of Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Coffee Collab With The Lore Lodge ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠COFFEE⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Bonus episodes as well as ad-free episodes on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Find us on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Join us on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Submit your relatives on our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Learn more about your ad choices. Visit megaphone.fm/adchoices

Prescription drug costs are a key health policy issue for both parties. President Trump has recently implimented his approach, which he's billed as "Trump Rx"On Today's Show:Chelsea Cirruzzo Washington Correspondent for STAT News explains what the Trump administration's new prescription drug marketplace aims to do, and who might save money by using it.

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

As 2026 begins, pharma leaders are placing sharper bets earlier while navigating increasing pressure across pricing, access, and evidence. In this episode, Matt Riordan, President of Putnam Market Access & Medical at Inizio Ignite, shares a candid, executive-level view of what leaders are prioritizing this year, where confidence is high, and where blind spots may limit impact. Drawing on real-world leadership conversations, the discussion explores how access and evidence expectations are shifting upstream and what it takes to pressure-test assumptions, align strategy earlier, and lead with greater clarity in 2026.Panel – Mindy McGrath, Matt Riordan  Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com. 

 The Pharma discuss the Super Bowl, NSC's new club record sale, and provide a quick update on preseason progress.  Thanks for listening! 

How do top sales leaders stay on top in 2026? Seasoned National Sales Director Kristy McCracken shares her secrets.About This EpisodeIn this episode of Medical Sales U, I sit down with Kristy McCracken, a veteran leader in medical devices and biologics. From managing multi-million dollar revenues to leading national teams at companies like Essity and Merck, Kristy knows what it takes to win.We dive deep into:The "Always Learning" Mindset: Why high-level executives are returning to the basics to stay competitive.Modern Networking: How to use LinkedIn and AI to find common ground with hiring managers today.Leadership & Coaching: Kristy shares a powerful story of how she coached an underperforming rep back to success.The Future of Med-Tech: Balancing high-tech AI tools with the "human touch" that closes deals.Whether you are trying to break into medical sales or you're a seasoned pro looking to reinvent your role, Kristy's insights on persistence and "sharpening the saw" are essential listening. Key Moments (Timestamps)00:00 – Introduction: The greatest winners never stop learning.02:15 – Kristy's journey: 20 years in Pharma and Medical Devices.04:30 – Why even National Sales Directors need a "Professional Community."07:45 – Breaking in vs. Leveling up: What has changed in 2026?11:10 – Leadership Deep Dive: Coaching a rep through a PIP (Performance Improvement Plan).15:30 – Networking Secrets: How Kristy landed her latest role using Dave's strategies.19:20 – The Human Element: Asking the "follow-up" question.23:10 – Advice for the next generation of medical sales leaders.Resources & LinksConnect with Kristy McCracken: https://www.linkedin.com/in/kristy-mccracken/READY TO BREAK INTO MEDICAL SALES? We help professionals transition into top-tier medical sales roles: medicalsalesu.com/Kristy mentioned that "Persistence is Key." What is the biggest rejection you've faced in your career, and how did you bounce back? Let us know in the comments!If you found value in this talk, please: SUBSCRIBE for more interviews with industry leaders. LIKE this video to help other medical sales professionals find us. HIT THE BELL so you never miss a coaching session.#MedicalSales #Leadership #CareerGrowth #SalesCoaching #MedTech #MedicalSalesU #Networking2026

Trump Launches TrumpRx.gov for Deep Prescription Drug Discounts. See omnystudio.com/listener for privacy information.

What happens when sobriety becomes a cultural priority, not just a personal choice? In this episode of That Sober Guy Podcast, we break down the Great American Recovery Plan and explore what it could mean if America truly shifted toward treatment over punishment, real recovery infrastructure, and accountability with support. This conversation goes beyond politics and into culture, identity, performance, and leadership, especially for men navigating business, family, and health in a world built on distraction and sedation. We also examine the broader recovery messaging gaining traction around: Mental health and addiction recovery Food quality and physical health Pharma dependence and long-term consequences Sobriety as personal sovereignty and leadership We ask the uncomfortable questions: What industries struggle when people get clear-minded? Why is avoidance normalized while discipline is questioned? What changes when men stop numbing and start leading? This episode isn't about telling you what to think, it's about helping you see the system clearly and decide for yourself. If you're interested in sobriety, recovery, mental clarity, personal growth, and high-performance living, this episode will challenge you, in a good way. Listen now and join the conversation. Sober Executive Performance Reset: A 12 Week Private Coaching Experience - APPLY HERE https://www.thatsoberguy.com/coaching Invite Shane to Speak - https://www.thatsoberguy.com/speaking Join “The Victory Circle”, our FREE Sober Guy Mens Community at https://www.thatsoberguy.com/offers/SvjjuEQ2/checkout Check out Shanes New Book, Sober Guy How Do I - https://a.co/d/81ZIgtE Tired of Drinking? Try Our 30 Day Quit Drinking Dude Challenge! - https://www.thatsoberguy.com/quit-drinking-alcohol-for-30-days For More Resources go to http://www.ThatSoberGuy.com Follow us on LinkedIn - https://www.linkedin.com/in/shane-ramer-7534bb257/ Follow us on Instagram @ThatSoberGuyPodcast Follow us on YouTube - https://www.youtube.com/thatsoberguypodcast  Follow us on X @ThatSoberGuyPod Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Kimchi One from Brightcore – Health Starts in the GutGet 25% off – Use Code: FLYOVER at https://mybrightcore.com/flyoverOr call (888) 315-8404 for up to 50% OFF your order and Free Shipping!On the Flyover Conservatives Show, we sat down with Dr. Kirk Elliott to break down the historic silver market plunge and what major banks were doing behind the scenes during the chaos. He explains how short covering, paper market manipulation, and sudden volatility created fear — while seasoned investors saw a strategic opportunity. Viewers will learn what this means for the future of precious metals, market stability, and how to think long-term when the financial system gets turbulent.TO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.comFollow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShowEpstein Thread: https://x.com/sayerjigmi/status/2018374717426503946?s=20Daily Wire Article: https://www.dailywire.com/news/no-humans-allowed-elon-musk-concerned-about-new-ai-platform-moltbook?author=Amanda+Prestigiacomo&category=undefined&elementPosition=28&row=3&rowHeadline=Latest+News&rowType=Vertical+Carousel&title=No+Humans+Allowed%3A+Elon+Musk+Concerned+About+New+AI+Platform+%E2%80%98Moltbook%E2%80%99 To Schedule A Time To Talk To Dr. Dr. Kirk Elliott Go To ▶ https://flyovergold.comOr Call 720-605-3900 BOOK: Thriving in the Economic Tsunami by Dr. Kirk Elliotthttps://www.amazon.com/Thriving-Economic-Tsunami-Kirk-Elliott/dp/B0BR8K2R5YCheck out our other economic updates here ▶  https://subsplash.com/flyoverconservatives/media/ms/+93kmffv-------------------------------------------

Google parent company Alphabet on the move as the tech giant reports results. The details and numbers from their latest quarter, and why tech analyst Gene Munster sees the stock topping the Mag7 group this year. Plus Eli Lilly and Novo Nordisk heading in opposite directions as the weight loss drug race enters its next leg. Why one top health care analyst is flagging management confidence and pricing algorithms as the difference makers.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Click On Picture To See Larger PictureTrump started to put all the pieces together starting back in 2017. He was setting the stage to remove NAFTA but he was not able to because congress put roadblocks into the legislation, so he transitioned it into the USMCA and now he has trapped Canada in it. Trade deals are power of the US, the US has the leverage and the [CB] knows it.  The [DS] along with Biden, Obama and Clinton are pushing the insurgency in this country. Walz believes he has the upper hand making a deal with Trump but this is going to backfire on him and Frey. The people in MN are already upset. The D’s believe they can shutdown the government and use the DHS funding to do it. But the OBBB is funding ICE so this is going to fail. Trump has the leverage and he weakening the [DS] every step of the way. The root cause is being exposed to the country.   Economy Big Picture: President Trump and Trade Using the Art of the Self-Fulfilling Prophecy Canada and the EU take trade and economic positions seemingly against U.S. interests. Simultaneously Mexico modifies all their trade positions to come into alignment with the USA. Yesterday, Mexican President Claudia Sheinbaum announced Mexico will no longer ship oil to Cuba.   When President Trump was asked about Prime Minister Mark Carney creating a new trade agreement with China, President Trump responded that he didn't care – it was irrelevant to him.  Yet, simultaneously inside the USMCA President Trump has the power to veto any trade agreement between Mexico or Canada and a non-member nation. So, why didn't President Trump care?  Easy, because in President Trump's mind there's not going to be a USMCA; so, he really doesn't care if Canada runs to violate it.  In real terms, Canada doing bilateral deals with other countries, especially deals potentially detrimental to the USA, only strengthens his position on dissolving the USMCA. If Canada violates the terms and spirit of the USMCA, it makes dispatch of the unliked trade agreement even easier.  Canada is helping President Trump remove the congressional justification they could use to block him.  If Canada is violating the USMCA (CUSMA), Congress is kneecapped from interference. Source: theconservativetreehouse.com (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); https://twitter.com/Geiger_Capital/status/2015924180160594345?s=20 https://twitter.com/KobeissiLetter/status/2015949123648909631?s=20  more than officially reported. Furthermore, China officially bought an additional 0.9 tonnes in December, pushing the total gold reserves to a record 2,306 tonnes. This also marked the 14th consecutive monthly purchase. In 2025, China's total reported gold purchases reached +27 tonnes. Assuming official purchases were 10% of what China is actually buying, this suggests China acquired +270 tonnes of physical gold in 2025. China is stockpiling gold like we are in a major crisis.    2025. Why hasn’t the Korean Legislature approved it?   Because the Korean Legislature hasn’t enacted our Historic Trade Agreement, which is their prerogative, I am hereby increasing South Korean TARIFFS on Autos, Lumber, Pharma, and all other Reciprocal TARIFFS, from 15% to 25%. Thank you for your attention to this matter!   DONALD J. TRUMP PRESIDENT OF THE UNITED STATES OF AMERICA Political/Rights DOGE https://twitter.com/alx/status/2015969948674203731?s=20 Geopolitical  War/Peace Medical/False Flags [DS] Agenda  https://twitter.com/VASenateGOP/status/2015208669336813823?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E2015208669336813823%7Ctwgr%5E5081d9eb1b9220fa690d082571ec929c4f0248cc%7Ctwcon%5Es1_c10&ref_url=https%3A%2F%2Fwww.thegatewaypundit.com%2F2026%2F01%2Fvirginia-democrats-now-seeking-double-their-own-pay%2F   pocket to line their own. TOTAL CON JOB! True. The Department of Justice did withdraw its request for arrest warrants against Don Lemon and four other individuals involved in the disruption of a church service in St. Paul, Minnesota, following a federal magistrate judge’s refusal to approve the related criminal complaints and an appeals court’s rejection of the DOJ’s emergency bid to compel the warrants.  While prosecutors could potentially pursue charges through alternative means, such as a grand jury, the specific action of withdrawing the warrant request aligns with the reported events https://twitter.com/mrddmia/status/2016208255677067439?s=20 https://twitter.com/EricBrakey/status/2015578832070123856?s=20 https://twitter.com/JayTownAlabama/status/2015584436230717786?s=20 According to recent data from the Giffords Law Center, the following 16 jurisdictions (15 states plus the District of Columbia) have explicit prohibitions on carrying firearms at demonstrations, protests, or licensed public gatherings. These restrictions vary by state, with some banning both concealed and open carry, while others target only one or apply under specific conditions (e.g., only for participants or permitted events). Note that laws can change, and some states have exceptions like for enhanced permit holders. State/Jurisdiction Concealed Carry Prohibited? Open Carry Prohibited? Notes Alabama Yes Yes Arkansas Yes No Applies only to participants in permitted demonstrations; enhanced CCW permittees are allowed. California No Yes Open carry banned generally. Connecticut No Yes Open carry banned generally. District of Columbia Yes Yes Florida No Yes Open carry banned generally. Hawaii Yes Yes Illinois Yes Yes Louisiana Yes No Applies to permitted demonstrations or parades. Maryland Yes Yes Mississippi Yes No Applies to permitted demonstrations or parades. Nebraska Yes No Applies at “political rallies” and fundraisers. New Jersey Yes Yes New York Yes Yes North Carolina Yes Yes Washington No Yes   https://twitter.com/EndWokeness/status/2015928285436203305?s=20 https://twitter.com/GuntherEagleman/status/2016211395273011469?s=20  gets disarmed… then shot. DHS is already tracking violent agitators who assault or obstruct officers (you know, felonies). Tom Homan pushing to make these interferers “famous” via database – names, faces, employers notified. The same crowd screaming “police state” will ignore he already assaulted officers once and walked   https://twitter.com/MrAndyNgo/status/2016235731602067586?s=20 https://twitter.com/JoeBiden/status/2016177515845283911?s=20   nation that tramples the 4th Amendment and tolerates our neighbors being terrorized. The people of Minnesota have stood strong — helping community members in unimaginable circumstances, speaking out against injustice when they see it, and holding our government accountable to the people. Minnesotans have reminded us all what it is to be American, and they have suffered enough at the hands of this Administration. Violence and terror have no place in the United States of America, especially when it's our own government targeting American citizens. No single person can destroy what America stands for and believes in, not even a President, if we — all of America — stand up and speak out. We know who we are. It’s time to show the world. More importantly, it’s time to show ourselves. Now, justice requires full, fair, and transparent investigations into the deaths of the two Americans who lost their lives in the city they called home. Jill and I are sending strength to the families and communities who love Alex Pretti and Renee Good as we all mourn their senseless deaths.   https://twitter.com/RyanSaavedra/status/2015985227798139267?s=20 https://twitter.com/JDVance/status/2015918587609772148?s=20 https://twitter.com/EricLDaugh/status/2015971665906110549?s=20 https://twitter.com/BillMelugin_/status/2016220055973855403?s=20     https://twitter.com/Recon1_ZA/status/2015778411650732184?s=20   It’s a rapid, involuntary reaction mediated by the brainstem, involving muscle tension, elevated heart rate, and adrenaline release. That repetitive exposure from them fatigues neural pathways but sustains heightened arousal, diverting cognitive resources from higher-order tasks to basic threat monitoring. It is an acute stressor, activating the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, which releases cortisol and adrenaline. Long exposure to this stuff impairs prefrontal cortex function critical for decision making. Pair this with the sheer annoyance, these tactics are a low-tech escalation of protest disruption, rooted in documented physiological responses to noise. In layman’s terms, they’re putting these officers on edge and triggering them to act. Pretti and Good was exactly what they wanted. It’s usually someone else who ends up dying and not the instigator. This is a great example. Watch the guy at the rear strike an officer against the head with an object. These officers, already on edge, are very likely to react to something like that. When someone ends up getting hurt, they’re all innocent. These events aren’t random. These are organised tactics. 80% of the people protesting aren’t aware that they’re being used by their own team as cannon fodder to generate outrage. https://twitter.com/DataRepublican/status/2015620564787105892?s=20   Tending the Soil on Chuffed. More about Tending the Soil later. What to know: the campaign is hosted by Chuffed and the first donation came from Jonny Soppotiuk, a Canada-based community organizer who is part of Chuffed leadership and specializes in fundraising. He is most likely a central figure in raising money. So, yeah. Starting to look like foreigners are playing a key role in all of this. That’s not all. I’ve put together a spreadsheet of 4000+ donors and their possible identities. https://twitter.com/davidson_f14299/status/2015874164679442499?s=20  Machine that's been running this country for decades. She's tied into the donors, the nonprofits, the consultants, the media networks — all the gears that keep the Machine turning. And look at what she just did. She tweeted out that webpage directing people to donate through a foreign‑operated platform. That's not some innocent little share. That's the Machine signaling to its own network — money pipelines, global partners, and political messaging all moving in sync. She knows exactly what she's amplifying and who benefits from it. And this isn't new for her. Look back at Russiagate. Her campaign funded the Steele dossier — the spark that set off years of investigations, headlines, and division. Even after the whole thing fell apart under scrutiny, the chaos it created was already locked in. That's how the Machine works: it doesn't need accuracy, it just needs momentum. And she's been one of the people who knows how to generate that momentum better than anyone. So where does she sit in the Machine? Right in the core. Not elected. Not accountable. Still pulling levers through the same networks she helped build. She's not operating inside the Machine — she's one of the people who designed the damn thing. And that's why her name keeps showing up. Not because she holds office. But because the Machine still runs on the structures she put in place — and every time she boosts a link, a cause, or a narrative, you can see those old gears turning all over again.  https://twitter.com/julie_kelly2/status/2015963638096429102?s=20 https://twitter.com/WarClandestine/status/2015941282237972649?s=20     President Trump's Plan  And we back you WHOLEHEARTEDLY in making it happen https://twitter.com/TriciaOhio/status/2015939758858371393?s=20   https://twitter.com/EricLDaugh/status/2015858856430055491?s=20   professional. He will continue to lead Customs and Border Patrol throughout and across the country — Mr. Homan will be the main point of contact on the ground in Minneapolis.” Hakeem Jeffries Backs Impeachment Push Against Kristi Noem House Minority Leader Hakeem Jeffries and his leadership team voiced support Tuesday for impeaching Department of Homeland Security (DHS) Secretary Kristi Noem. Nearly 150 House Democrats have sponsored articles of impeachment against Noem, first unveiled by Democratic Illinois Rep. Robin Kelly on Jan. 14, but Jeffries had not previously backed the impeachment push. Jeffries vowed Tuesday that House Democrats will launch impeachment proceedings against Noem if President Donald Trump does not fire her. Source: dailycaller.com https://twitter.com/disclosetv/status/2016203259900317988?s=20   https://twitter.com/amuse/status/2016218361844174956?s=20   Minnesota State Patrol has now been activated. They could have done this the whole time, but it wasn't until after the call between Walz and Trump, and the discovery of the Signal groups involving Minnesota government officials, that this happened.   https://twitter.com/CynicalPublius/status/2015868419187544417?s=20 https://twitter.com/derrickvanorden/status/2015808200495312963?s=20 Counterinsurgency may be defined as ‘comprehensive civilian and military efforts taken to simultaneously defeat and contain insurgency and address its root causes'. Defeat refers to actively dismantling the insurgent group’s capabilities—through kinetic operations (e.g., raids, airstrikes) to kill or capture leaders, disrupt supply lines, and degrade their fighting strength. Contain means preventing the insurgency from spreading or escalating. This could involve securing borders, isolating insurgent areas, or using psychological operations (psyops) to undermine their recruitment and propaganda. The “simultaneously” part stresses that these aren’t sequential steps; they happen in parallel. You can’t just “contain” without addressing threats, nor can you defeat an insurgency if it keeps regenerating in new areas. Key challenge: Insurgents often blend into the civilian population, making it hard to target them without collateral damage, which can create more enemies. 3. Address Its Root Causes Insurgencies don’t arise in a vacuum; they’re often driven by underlying issues like political exclusion, economic inequality, corruption, ethnic tensions, or lack of basic services. The definition insists that long-term success requires tackling these “root causes” to prevent resurgence. This might include reforms such as land redistribution, anti-corruption drives, inclusive governance, or economic development programs. Without this, military victories are temporary. For instance, historical cases like the Malayan Emergency (1948–1960) succeeded partly because British forces combined military action with resettlement programs and political concessions that addressed Malay grievances against colonial rule. Broader Context and Principles Population-Centric Approach: Modern COIN doctrine, influenced by thinkers like David Galula or modern adaptations, views the local population as the “center of gravity.” The goal is to protect civilians, gain their trust, and separate them from insurgents—often summarized as “clear, hold, build” (clear insurgents from an area, hold it securely, and build sustainable institutions). Challenges and Criticisms: COIN is resource-intensive, time-consuming, and politically fraught. It can lead to prolonged conflicts, human rights abuses, or mission creep. Critics argue it sometimes ignores cultural contexts or over-relies on foreign intervention, as seen in Vietnam or Iraq. Success Factors: Effective COIN requires unity of effort (coordination between allies), intelligence-driven operations, and adaptability. Metrics for success go beyond body counts to include governance improvements and reduced violence. In essence, this definition portrays counterinsurgency as a balanced, enduring campaign that blends force with reform to not just suppress rebellion but eliminate the conditions that sustain it.    https://twitter.com/EricLDaugh/status/2015886441063055779?s=20 patriots need all the support they can get!  Background on the “Big Beautiful Bill” and ICE Funding In 2025, Republicans passed the “One Big Beautiful Bill Act” (often referred to by President Trump as the “Big Beautiful Bill”), which allocated approximately $75 billion to Immigration and Customs Enforcement (ICE) over four years. This funding was separate from annual appropriations and effectively tripled ICE’s budget, providing a multi-year “slush fund” for immigration enforcement, including deportations.  This bill was part of Trump’s broader immigration agenda and bypassed traditional yearly funding processes, allowing ICE to operate independently of short-term congressional battles. Current Shutdown Threat and Democrats’ Strategy Democrats, led by figures like Senate Minority Leader Chuck Schumer and Sens. Patty Murray, Chris Murphy, and others, have vowed to block the Department of Homeland Security (DHS) funding bill in the Senate. This bill includes $64.4 billion for DHS overall, with about $10 billion specifically for ICE in the current fiscal year.  Why the Shutdown Won’t Defund ICE Even prominent Democrats like Sen. Murray acknowledge that a shutdown or continuing resolution (short-term funding patch) won’t restrain ICE. The agency can draw from the $75 billion already secured via the Big Beautiful Bill, allowing operations to continue uninterrupted under Trump’s “law-and-order” immigration crackdown.  A shutdown would primarily affect non-ICE parts of DHS (e.g., TSA, FEMA, Coast Guard) and other bundled departments, forcing some federal workers to go without pay while ICE remains funded and operational.  Republican Position and “Upper Hand” The White House and GOP leaders like Speaker Mike Johnson are not yielding, insisting on passing the full package without decoupling DHS funding. They view Democratic threats as ineffective since ICE’s core operations are protected by the prior bill.  The House has already passed the DHS bill with some Democratic support, putting pressure on the Senate. Republicans are framing this as Democrats prioritizing protests over essential services, giving the GOP leverage in negotiations.    https://twitter.com/AwakenedOutlaw/status/2015946190219837842?s=20   themselves, and engage in thoughtful discourse and/or express outrage against the wholesale ridiculousness of not allowing the government to do its job and protect us…and they do so for months on matters that most would never have otherwise engaged in AND would otherwise slip out of the news cycle quickly.    The Supreme Court ends up taking the case and rules (correctly) in favor of his administration. Piece by piece through this process, legal precedence is secured. Which, as it turns out, was deemed necessary to help secure the future of our Republic writ large. Lather. Rinse. Repeat. This implies that we are directly involved in an educational process, if you will, as we all progress through the realignment. Advantage: America’s future https://twitter.com/AGPamBondi/status/2015932965528764622?s=20   violent agitators. The DOJ went to court. We got a temporary stay. NOW, the 8th Circuit has fully agreed that this reckless attempt to undermine law enforcement cannot stand. 8th Circuit Court of Appeals rules in favor of Trump admin allowing ICE agents to arrest, detain, pepper-spray or retaliate against violent anti-ICE rioters, in Minneapolis, without probable cause   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");